SAP's Buyback and AstraZeneca Bet Converge on a Single Date: January 28, 2027

SAP has kept its share repurchase programme running through the autumn, picking up another 95.4 million euros of its own stock between 2 and 6 November. Since the end of July 2026 the group has bought back roughly 9.6 million shares for about 1.66 billion euros — a capital return effort that now sits alongside a far larger question for investors: whether the cloud business can carry the growth story through to the preliminary annual results on 28 January 2027.

The buyback arithmetic has shifted markedly. Between April and August 2025 SAP paid an average of 257.60 euros per share; at today's 211.50 euros, the recent tranches are being executed well below those levels. Cheaper entry prices only make sense as capital allocation, though, if the operating business keeps generating the cash that funds them — and that is where the third-quarter figures come in.

Cloud Momentum Underpins the Cash Engine

Cloud revenue climbed 26% to 6.67 billion euros in the third quarter of 2026, with the short-term cloud backlog up 28% to 24.1 billion euros. Total revenue for the quarter reached 10.27 billion euros, while adjusted operating profit rose 18% to 3.03 billion euros. For the full year SAP expects free cash flow of around 10 billion euros and, for 2026, a currency-adjusted adjusted operating profit of 11.8 to 12.2 billion euros. Those targets are the hinge on which the buyback case turns: if the cash arrives as promised, further repurchases rest on solid ground.

The growth trajectory also drew a more bullish read from the sell side. Reports on Monday said SAP was upgraded from "Neutral" to "Overweight", with the price target lifted from 175 to 275 euros. The rationale cited the shift of AI pilot projects into productive deployment and SAP's improved AI offering.

AstraZeneca Hands SAP a Large-Scale Test Case

That AI narrative gained a concrete customer reference on Tuesday, when SAP announced an expansion of its partnership with AstraZeneca. The pharmaceutical group plans to move to SAP Cloud ERP Private under RISE with SAP, covering its entire SAP system landscape — a project SAP describes as one of the largest in the life-sciences sector. Unlike a rollout confined to individual applications, a company-wide migration gives the cloud strategy a broader operational proving ground, and its weight for the growth thesis rises if execution proceeds on schedule.

AstraZeneca is additionally evaluating SAP Business AI, Joule and agent-based applications. Those are at a different stage — assessment rather than commitment — and the potential benefit to SAP depends on whether evaluation turns into actual use. A positive scenario would see the broad cloud migration paired with growing adoption of AI tools, deepening the relationship beyond the ERP move. SAP and VF Corporation opened a practical testing ground for exactly this on the previous day, with S.Fashion in Walldorf, where AI-supported processes for inventory, order management and replenishment are being trialled.

Execution Risk Cuts Both Ways

The genuine risk is a gap in timing between expectations and operational progress. Migrating an entire system landscape is a wide-ranging undertaking; if it advances more slowly than investors anticipate, the growth narrative built on it could lose conviction. On the AI side, the outlook hinges on customer decisions — AstraZeneca is still evaluating, and the step from assessment to deployment could take longer or prove narrower than hoped.

A more favourable analyst rating raises the bar for coming results as well. Should operating performance meet those expectations, the valuation case is reinforced; if cloud momentum lags, the debate is likely to centre on execution rather than the potential of individual applications. For investors, that argues for weighting confirmed business performance more heavily than a possible later expansion of AI usage.

What January Will Settle

SAP has scheduled its preliminary results for the fourth quarter and full year 2026 for 28 January 2027, alongside an analyst and investor conference and the annual press conference. Until then, the test is straightforward: cloud growth supports the stock as long as it translates into rising profits and the expected cash inflows — and that same link determines how convincing the continued buybacks look as a use of capital.